Medical Tech Outlook Weekly Brief
Be first to read the latest tech news, Industry Leader's Insights, and CIO interviews of medium and large enterprises exclusively from Medical Tech Outlook
The award entails the efforts and strategies that the Venture Capitalists in the MedTech space that they have implemented while investing during and post the pandemic space to assist their inevsted portfolio of companies in creating innovation.
CEO, Propel(x)
Swati Chaturvedi is the co-founder and CEO of Propel(x) – an investment platform that enables accredited investors worldwide to invest in startups and venture capital funds. Ms. Chaturvedi has a long history of working in the alternative investments space and is the founder of the MIT Alumni Angel Investors group. She founded and led the group 2013–2015, and continues to be on the screening committee. Prior to starting Propel(x), Swati has worked as an investment professional at Exigen Capital, Siemens Venture Capital and Temasek Holdings. She has also been a management consultant working across a variety of industries. Ms. Chaturvedi holds an MBA degree from MIT Sloan School of Management, an M.S. degree from MIT, an M.S. degree from UC Berkeley, and a Bachelor’s degree from the Indian Institute of Technology, Roorkee. She has FINRA Series 7, 24 and 63 licenses. Read Also: An Investment Platform for Deep Technology By: Swati Chaturvedi, CEO, Propel(x) and Partner, Newton Fund
Andrew medical technology partner
Andrew ElBardissi, M.D., is a Partner on the Medical Technologies team and joined the Firm in 2017. Prior to Deerfield, Dr. ElBardissi was a Principal at Longitude Capital, where he focused on investments in medtech and biotechnology. Before that, he was an Associate in JPMorgan’s healthcare investment banking practice. Dr. ElBardissi received residency training in General Surgery at Harvard Medical School’s Brigham and Women’s Hospital and in Cardiothoracic Surgery at Stanford University. He has been independently funded by the National Institutes of Health and the Agency for Healthcare Research and Quality, has authored over 30 publications in leading peer-reviewed scientific journals and has presented his research at numerous medical and surgical conferences. Dr. ElBardissi holds an M.D. from the Mayo Clinic, an M.P.H. in Quantitative Methods from Harvard University, an M.B.A. from Harvard Business School and a B.S. with honors in Biology (Phi Beta Kappa) from the Schreyer Honors College at the Pennsylvania State University. Read Also: Venture Capital's role in Driving MedTech Innovation By: Andrew ElBardissi, MD, Partner at Deerfield Management
“Deerfield also places cardinal value in looking for companies that have category-defining technologies that are truly disruptive”
M.D., Managing Partner and leader of the Healthcare Investment Team at InterWest Partners
Gil joined InterWest in 1996. As Managing Partner of the firm and the leader of InterWest’s Healthcare investment team, he invests in a broad array of healthcare opportunities, with a special interest in ophthalmology, digital health, and AI/robotics. Gil pioneered InterWest’s highly successful ophthalmology franchise. He was an early investor in Avedro, Glaukos, LenSx, and IntraLase, all category-creating ophthalmic companies that became standard-of-care for eye surgery around the world. As a successful digital health investor, Gil also built this important franchise for InterWest. He was the founding institutional investor in Doximity, helping to build it into the leading digital network for physicians, engaging over 80% of U.S. doctors, with over one million users. Gil and InterWest supported Doximity’s June 2021 blockbuster $4B value IPO, which subsequently generated the largest investment return in InterWest’s history. Prior to that, he led the Series A of Epocrates, the first mobile application for physicians, serving on the board through its 2011 IPO and continuing as an investor through its 2013 acquisition by athenahealth. Gil currently serves as an independent board member of Glaukos (NYSE: GKOS), a pioneering ophthalmic technology company focused on the development and commercialization of breakthrough devices and drugs to transform the treatment of eye diseases, STAAR Surgical (NASDAQ: STAA), a leading ophthalmology company commercializing the EVO implantable contact lens for nearsightedness, and Orbis International, a global not-for-profit organization focused on preventing blindness. He is also a co-founder and program director of Eyecelerator, a first-of-kind ophthalmology innovation conference supported by a joint venture of the American Academy of Ophthalmology and the American Society of Cataract and Refractive Surgery. Previously, he helped to launch the Ophthalmology Innovation Summit (OIS), an ophthalmology business conference where he was an advisor and founding co-chairman from 2009 to 2019. He is a former board member and lead investor in Doximity (NYSE: DOCS), Avedro (NASDAQ: AVDR, acquired by Glaukos), Epocrates (NASDAQ: EPOC, acquired by athenahealth), LenSx Lasers (acquired by Alcon), IntraLase (NASDAQ: ILSE, acquired by AMO), Neuronetics (NASDAQ: STIM), Restoration Robotics (NASDAQ: VERO, acquired by Venus Concept), and GoCheck. A former practicing eye surgeon, Gil completed an ophthalmology residency at Wills Eye Hospital and a retina fellowship at Massachusetts Eye and Ear Infirmary as a Heed Foundation fellow. He has a BA from Harvard University, an MD from the University of Pennsylvania and an MBA from Stanford University. Read Also: How can you Drive Innovation by Investing in People? By: Gilbert H. Kliman, M.D., Managing Partner and leader of the Healthcare Investment Team at InterWest Partners “We want to see a strong leader in the CEO and a strong technical team, because most things we're investing in require visionary leadership and are highly technical”
Partner, New Enterprise Associates
Andrew Schoen joined NEA in 2014 and is a Partner focused on enterprise technology investments. He has served as a board director or observer for Aigen, Berkshire Grey (NASDAQ), CCP Games (acquired), Clarifai, Dandelion, Duolingo, Expanse (acquired), IonQ (NYSE), Merge API, and ThreatQ. In addition, he has been involved with NEA’s investments in Beyond Identity, FiscalNote, Onshape (acquired), Pentaho (acquired), PlayVS, Pocket (acquired), Rocket Chat, Theorycraft, Timescale, and Wispr AI. Andrew is also a member of NEA’s Asia investing team and has been involved with NEA’s investments in ByteDance, Xsky and Zuoyebang. In 2018, Andrew was named to the Forbes 30 Under 30 list in Venture Capital. Prior to joining NEA, Andrew was a member of Blackstone’s M&A team in New York. Andrew previously co-founded the digital media company Flicstart (acquired)
Partner, SOSV
Susan Schofer, the Partner at SOSV / HAX is an experienced startup operator with 15+ years in roles spanning R&D, product development, product management, strategy, partnerships, and business development. She is a climate tech venture capital investor evaluating and working closely with broad range of technical & scientific founders to accelerate de-risking & commercialization of impactful innovation. She is a global executive with successful track record leading climate tech and sustainability-focused innovation in the biotech, materials, consumer, and chemical industries. She has accomplished corporate development and business development leader with expertise evaluating white-space opportunities, creating business strategy, and carrying out all aspects of strategic partnerships throughout phases of deal cycle, including opportunity assessment and initial partner engagement, due diligence processes, crafting of key terms, and negotiation to close definitive agreements.
Senior Managing Director, Connecticut Innovations
Peter Longo has spent over 25 years in numerous roles at Connecticut Innovations. Peter is responsible for evaluating investment opportunities, structuring investments and monitoring portfolio companies through active board participation. Peter’s past CII investments include: Achillion Pharmaceuticals (IPO), Cardium Health (acquired by Centene), CYA Technologies (acquired by enChoice), Aventri fka eTouches (acquired by HGGC), NeuVis (acquired by Rational Software), Nufern (acquired by Rofin-Sinar), SilverSky (acquired by BAE Systems), Payveris (acquired by Paymentus), PCC Technology Group (acquired by Clearview Capital), Device42 (acquired by private equity syndicate) and Post-N-Track (management buyout).
Co-Founder, The General Partnership
Phin Barnes is a Sneakerhead and VC focused on redefining partnership in the world of venture capital with The General Partnership. He grew from unpaid intern to managing partner at First Round Capital, worked at AND 1 Basketball from “day 2″ and founded a fitness video game company. The best companies have incredible people, world class products, superior distribution and access to capital. The General Partnership is designed for maximum impact in each of these areas for the select group of founders we serve.
Managing Director and CEO, Partners for Growth
Andrew co-founded Partners for Growth with Don Campbell in 2004 and has been structuring custom financing for technology companies for the past 35 years. Prior to forming PFG, Andrew and Don together managed Hambrecht & Quist Guaranty Finance (HQGF), the lending practice of San Francisco technology focused investment bank Hambrecht & Quist. Andrew held a variety of senior roles during his tenure at Hambrecht & Quest including General Partner of Access Technology Partners (a venture capital fund), a Managing Director of the H&Q Investment Bank, and President of HQGF. Following Hambrecht & Quist’s acquisition by Chase and merger with JP Morgan, Andrew was a General Partner with JP Morgan’s buyout.
General Partner, U.S. Venture Partners
Jacques Benkoski is an experienced Board Member with a demonstrated history of working in the computer software industry. He has strong business development professional skilled in Cloud, Cybersecurity, and Enterprise Software. He is a former entrepreneur with deep technical background and hands-on sales management experience. U.S. Venture Partners (USVP) is a leading Silicon valley-based venture capital firm, helping entrepreneurs build world-class companies since 1981. U.S. Venture Partners (USVP), is a venture capital investment firm headquartered in Menlo Park, California in the heart of Silicon Valley focusing on investments in an array of segments including enterprise software, cyber security, consumer, e-commerce, healthcare, and IT-enabled healthcare services.
Partner, Santé
Omar Khalil rejoined Santé in 2020, concentrates on the biotechnology and medical technology spaces, and manages the Boston Office. Prior to that, he held senior leadership roles with Baxter International, Baxalta (now part of Takeda) and Kaléo, a commercial-stage biopharmaceutical company developing a novel drug delivery platform primarily focused in Allergy & Immunology. He has managed and led businesses ranging from early clinical development, commercial launch and scaling to more than $3 Billion in annual sales. He spent four years at Santé as a Principal, investing Funds I and II. Earlier in his career, he worked at McKinsey & Company in the healthcare practice, where he served leading medical device and pharmaceutical companies. He received his MSE and BSE in Biomedical Engineering summa cum laude from the University of Michigan with a concentration in Tissue Engineering.
